Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTNM NASDAQ:MESO NYSE:NUVB NASDAQ:URGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTNMContineum Therapeutics$14.73+6.0%$13.50$5.07▼$16.91$519.67M0.7491,989 shs268,272 shsMESOMesoblast$16.30-0.7%$14.91$12.66▼$21.50$2.13B2.08297,525 shs166,092 shsNUVBNuvation Bio$6.55+1.9%$5.31$2.18▼$9.75$2.24B1.529.55 million shs7.70 million shsURGNUrogen Pharma$42.06-3.9%$33.36$15.86▼$43.93$2.13B1.56809,744 shs486,929 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTNMContineum Therapeutics+5.97%+0.68%+26.76%+18.60%+184.36%MESOMesoblast-0.73%-10.64%+5.16%+5.16%+8.09%NUVBNuvation Bio+2.31%+11.26%+13.47%+29.63%+179.45%URGNUrogen Pharma-3.93%+5.68%+20.21%+73.02%+148.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTNMContineum Therapeutics$14.73+6.0%$13.50$5.07▼$16.91$519.67M0.7491,989 shs268,272 shsMESOMesoblast$16.30-0.7%$14.91$12.66▼$21.50$2.13B2.08297,525 shs166,092 shsNUVBNuvation Bio$6.55+1.9%$5.31$2.18▼$9.75$2.24B1.529.55 million shs7.70 million shsURGNUrogen Pharma$42.06-3.9%$33.36$15.86▼$43.93$2.13B1.56809,744 shs486,929 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTNMContineum Therapeutics+5.97%+0.68%+26.76%+18.60%+184.36%MESOMesoblast-0.73%-10.64%+5.16%+5.16%+8.09%NUVBNuvation Bio+2.31%+11.26%+13.47%+29.63%+179.45%URGNUrogen Pharma-3.93%+5.68%+20.21%+73.02%+148.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTNMContineum Therapeutics 2.40Hold$20.0035.78% UpsideMESOMesoblast 2.50Moderate BuyN/AN/ANUVBNuvation Bio 2.64Moderate Buy$12.3888.84% UpsideURGNUrogen Pharma 2.80Moderate Buy$41.63-1.03% DownsideCurrent Analyst Ratings BreakdownLatest CTNM, NUVB, MESO, and URGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/22/2026NUVBNuvation Bio Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform7/21/2026URGNUrogen Pharma GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $42.007/17/2026CTNMContineum Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026MESOMesoblast Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/17/2026NUVBNuvation Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026URGNUrogen Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/16/2026URGNUrogen Pharma OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$40.00 ➝ $50.007/15/2026URGNUrogen Pharma The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$44.007/9/2026URGNUrogen Pharma UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/9/2026URGNUrogen Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/7/2026NUVBNuvation Bio Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$20.00 ➝ $19.00(Data available from 7/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTNMContineum Therapeutics$50M11.02N/AN/A$6.99 per share2.11MESOMesoblast$17.20M122.69N/AN/A$4.67 per share3.49NUVBNuvation Bio$62.90M36.28N/AN/A$0.88 per share7.45URGNUrogen Pharma$109.79M18.66N/AN/A($2.25) per share-18.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTNMContineum Therapeutics-$59.98M-$1.95N/AN/AN/AN/A-27.09%-25.64%8/4/2026 (Estimated)MESOMesoblast-$102.14M-$0.28N/AN/AN/AN/AN/AN/A9/4/2026 (Estimated)NUVBNuvation Bio-$204.63M-$0.43N/AN/AN/A-102.06%-44.10%-23.80%8/6/2026 (Estimated)URGNUrogen Pharma-$153.49M-$2.75N/A27.49N/A-94.83%N/A-62.85%8/6/2026 (Estimated)Latest CTNM, NUVB, MESO, and URGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026NUVBNuvation Bio-$0.15N/AN/AN/A$26.88 millionN/A8/6/2026Q2 2026URGNUrogen Pharma-$0.2713N/AN/AN/A$63.53 millionN/A8/4/2026Q2 2026CTNMContineum Therapeutics-$0.46N/AN/AN/AN/AN/A5/7/2026Q1 2026URGNUrogen Pharma-$0.4824-$0.47+$0.0124-$0.47$44.83 million$50.96 million5/5/2026Q1 2026CTNMContineum Therapeutics-$0.55-$0.39+$0.16-$0.39N/AN/A5/4/2026Q1 2026NUVBNuvation Bio-$0.0280$0.01+$0.0380$0.01$66.22 million$83.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCTNMContineum TherapeuticsN/AN/AN/AN/AN/AMESOMesoblastN/AN/AN/AN/AN/ANUVBNuvation BioN/AN/AN/AN/AN/AURGNUrogen PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTNMContineum TherapeuticsN/A38.0038.00MESOMesoblast0.101.581.41NUVBNuvation Bio0.157.447.24URGNUrogen PharmaN/A4.694.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTNMContineum TherapeuticsN/AMESOMesoblast1.43%NUVBNuvation Bio61.67%URGNUrogen Pharma91.29%Insider OwnershipCompanyInsider OwnershipCTNMContineum Therapeutics7.90%MESOMesoblast18.80%NUVBNuvation Bio30.11%URGNUrogen Pharma4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTNMContineum Therapeutics3137.39 million34.43 millionN/AMESOMesoblast80129.46 million105.12 millionOptionableNUVBNuvation Bio60348.20 million243.36 millionOptionableURGNUrogen Pharma20048.72 million46.38 millionOptionableCTNM, NUVB, MESO, and URGN HeadlinesRecent News About These CompaniesUrogen Pharma (NASDAQ:URGN) Reaches New 12-Month High - Here's What HappenedJuly 21 at 4:19 AM | marketbeat.comUroGen Pharma: Reimbursement Is Turning Zusduri Into A Workflow MoatJuly 20 at 3:00 PM | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Urogen Pharma (URGN) and vTv Therapeutics (VTVT)July 17, 2026 | theglobeandmail.comShort sellers are betting against UroGen Pharma stock, but Wall Street expects 263% earnings growth in 2027July 17, 2026 | msn.comUroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ...July 15, 2026 | caledonianrecord.comCUroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103July 15, 2026 | globenewswire.comUrogen Pharma (NASDAQ:URGN) Reaches New 52-Week High - What's Next?July 15, 2026 | marketbeat.comUroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% RunJuly 12, 2026 | fool.comUrogen Pharma (NASDAQ:URGN) Insider Sells 10,000 SharesJuly 11, 2026 | insidertrades.comUrogen Pharma (NASDAQ:URGN) Insider Mark Schoenberg Sells 10,000 SharesJuly 10, 2026 | marketbeat.comUroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder CancerJuly 8, 2026 | globenewswire.comUrogen Pharma (URGN) is a Great Momentum Stock: Should You Buy?July 7, 2026 | zacks.comIs UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares?June 30, 2026 | fool.comMark Schoenberg Sells 10,000 Shares of Urogen Pharma (NASDAQ:URGN) StockJune 25, 2026 | insidertrades.comUroGen Shareholders Approve Governance, Compensation and Auditor ChangesJune 23, 2026 | tipranks.comIs UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?June 14, 2026 | fool.comGuggenheim Remains a Buy on Urogen Pharma (URGN)June 10, 2026 | theglobeandmail.comUroGen Pharma Ltd. (URGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 10, 2026 | seekingalpha.comMark Schoenberg Sells 5,222 Shares of Urogen Pharma (NASDAQ:URGN) StockJune 10, 2026 | insidertrades.comUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 5, 2026 | globenewswire.comUroGen settles with Teva over Jelmyto patent disputeJune 3, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCTNM, NUVB, MESO, and URGN Company DescriptionsContineum Therapeutics NASDAQ:CTNM$14.73 +0.83 (+5.97%) Closing price 07/22/2026 04:00 PM EasternExtended Trading$14.74 +0.01 (+0.10%) As of 07/22/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.Mesoblast NASDAQ:MESO$16.30 -0.12 (-0.73%) Closing price 07/22/2026 04:00 PM EasternExtended Trading$16.31 +0.01 (+0.06%) As of 07/22/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Nuvation Bio NYSE:NUVB$6.55 +0.12 (+1.91%) Closing price 07/22/2026 03:59 PM EasternExtended Trading$6.55 0.00 (-0.05%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.Urogen Pharma NASDAQ:URGN$42.06 -1.72 (-3.93%) Closing price 07/22/2026 04:00 PM EasternExtended Trading$41.92 -0.14 (-0.34%) As of 04:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Robotaxi Mode Engaged: Tesla Starts Monetizing Its Florida Fleet Insider Moves Are Sending Mixed Signals Across the Tech Sector Boxabl Disrupts Housing With A Tiny Float IPO Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying Velo3D Forges a New Reality After Its Sharp Stock Sell-Off Why Apple Could Be the Last One Standing in the Tech Wreck Archer and Anduril Put ACHR Stock on a New Defense Flight Path 3M's Redemption Arc: Can Q2 Earnings Change the Narrative? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
